Radiation therapy after chemotherapy for bile duct and gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving additional radiation therapy (called consolidative radiotherapy) to people with bile duct or gallbladder cancer that hasn't grown after initial chemotherapy can help control the disease for longer. It is for people whose cancer has spread to a limited number of places (oligometastatic) or is locally advanced and can't be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bile duct, gallbladder, or related cancer that cannot be removed with surgery.
- You have completed four cycles of first-line chemotherapy or targeted therapy, and the disease hasn't grown.
- You have no more than five areas of cancer spread, with no more than three in any one organ (like liver or lungs).
- All areas of cancer can be safely treated with radiation.
- You are 18 or older, able to care for yourself (ECOG score 0-1), and expected to live more than 3 months.
- Your blood counts and liver/kidney function meet the trial's safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.